ZIM Laboratories Receives Australian Marketing Approval for Migraine Drug

MT Newswires Live

2025/07/21

ZIM Laboratories (NSE:ZIMLAB, BOM:541400) has received Marketing Authorization from Australia's Therapeutic Goods Administration (TGA) for its central nervous system product, Rizatriptan Benzoate Orally Disintegrating Films, according to a Monday filing.

The approval was granted through its Australian subsidiary, ZIMTAS and marks the company's first regulatory approval in Australia, the filing said.

Rizatriptan is used for the acute treatment of migraine in adults. The approval paves the way for the commercial launch of the drug in Australia, the company said in the filing.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553471605"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553471605\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553471605?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-21 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553471605","market":"hk","top_or_hot":-1,"title":"ZIM Laboratories Receives Australian Marketing Approval for Migraine Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ZIM\">ZIM</a> Laboratories (NSE:ZIMLAB, BOM:541400) has received Marketing Authorization from Australia's Therapeutic Goods Administration (TGA) for its central nervous system product, Rizatriptan Benzoate Orally Disintegrating Films, according to a Monday filing.</p><p>The approval was granted through its Australian subsidiary, ZIMTAS and marks the company's first regulatory approval in Australia, the filing said.</p><p>Rizatriptan is used for the acute treatment of migraine in adults. The approval paves the way for the commercial launch of the drug in Australia, the company said in the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZIM Laboratories Receives Australian Marketing Approval for Migraine Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZIM Laboratories Receives Australian Marketing Approval for Migraine Drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-07-21 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ZIM\">ZIM</a> Laboratories (NSE:ZIMLAB, BOM:541400) has received Marketing Authorization from Australia's Therapeutic Goods Administration (TGA) for its central nervous system product, Rizatriptan Benzoate Orally Disintegrating Films, according to a Monday filing.</p><p>The approval was granted through its Australian subsidiary, ZIMTAS and marks the company's first regulatory approval in Australia, the filing said.</p><p>Rizatriptan is used for the acute treatment of migraine in adults. The approval paves the way for the commercial launch of the drug in Australia, the company said in the filing.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4021","symbol_name":"海運","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2553471605","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553471605","pubTimestamp":1753099314,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ZIM Laboratories  has received Marketing Authorization from Australia's Therapeutic Goods Administration  for its central nervous system product, Rizatriptan Benzoate Orally Disintegrating Films, according to a Monday filing.The approval was granted through its Australian subsidiary, ZIMTAS and marks the company's first regulatory approval in Australia, the filing said.Rizatriptan is used for the acute treatment of migraine in adults. The approval paves the way for the commercial launch of the drug in Australia, the company said in the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4021":"海运","XJO.AU":"标普/澳交所 200指数","XKO.AU":"标普/澳交所 300指数","BK4588":"碎股","BK4213":"石油与天然气的勘探与生产","ZIM":"以星航运","TGA":"Transglobe Energy Corp","BK4585":"ETF&股票定投概念","XAO.AU":"标普/澳交所 普通股指数","TGA.AU":"Thorn GroupLtd","BK7001":"电脑与电子产品零售"},"translate_title":"以星实验室偏头痛药物获得澳大利亚上市批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":1,"ZIM":1,"TGA":1,"TGA.AU":1,"XAO.AU":1,"XJO.AU":1},"content_text":"ZIM Laboratories (NSE:ZIMLAB, BOM:541400) has received Marketing Authorization from Australia's Therapeutic Goods Administration (TGA) for its central nervous system product, Rizatriptan Benzoate Orally Disintegrating Films, according to a Monday filing.The approval was granted through its Australian subsidiary, ZIMTAS and marks the company's first regulatory approval in Australia, the filing said.Rizatriptan is used for the acute treatment of migraine in adults. The approval paves the way for the commercial launch of the drug in Australia, the company said in the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}